# Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

> **NCT01003418** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine
- **BIOLOGICAL:** Infanrix™-IPV/Hib
- **BIOLOGICAL:** Prevenar

## Key facts

- **NCT ID:** NCT01003418
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-17
- **Primary completion:** 2010-11-25
- **Final completion:** 2010-11-25
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated prematurely for logistic reasons, not related to safety or efficacy of the vaccine.
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003418, "Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01003418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*